SVP, Chief of Staff Ancona Margaret covered exercise/tax liability with 2,622 shares, decreasing direct ownership by 2% to 128,684 units (SEC Form 4)

$MYGN
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Get the next $MYGN alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ancona Margaret

(Last) (First) (Middle)
322 NORTH 2200 WEST

(Street)
SALT LAKE CITY UT 84116

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Chief of Staff
3. Date of Earliest Transaction (Month/Day/Year)
03/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/22/2025 F 718(1) D $10.01 130,588 D
Common Stock 03/22/2025 F 1,904(2) D $10.01 128,684 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025.
2. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025.
Remarks:
By: Justin Hunter For: Margaret Ancona 03/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $MYGN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MYGN

DatePrice TargetRatingAnalyst
3/12/2025$11.50 → $12.50Neutral → Overweight
Piper Sandler
2/12/2025$29.00Buy
Craig Hallum
12/10/2024$18.00Neutral
UBS
12/9/2024$30.00 → $21.00Outperform → Market Perform
Leerink Partners
9/19/2024$32.00Equal-Weight
Morgan Stanley
8/28/2024$35.00Overweight
Wells Fargo
6/27/2024$29.00Sector Outperform
Scotiabank
6/3/2024$20.00Underperform
Jefferies
More analyst ratings

$MYGN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

    SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi's risk assessment program and access to breast specialists with Myriad's MyRisk® with RiskScore® Hereditary Cancer Test. "After losing my mom to breast cancer and my own breast cancer diagnosis, I am passionate about eradicating late-stage breast cancer by helping women understand their risk and access the care they nee

    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Myriad Genetics Announces Senior Leadership Transition

    SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year. "Since joining Myriad in December 2023, Sam has played an integral role in sh

    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

    SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ's AI technology platform for prostate cancer, in the United States. Machine learning and AI-enabled diagnostics are transforming the way clinicians approach cancer patient care. Adding PATHOMIQ_PRAD to Myriad's Oncology Solutions allows

    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$MYGN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MYGN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MYGN
SEC Filings

See more

$MYGN
Leadership Updates

Live Leadership Updates

See more
  • Myriad Genetics Announces Senior Leadership Transition

    SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year. "Since joining Myriad in December 2023, Sam has played an integral role in sh

    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    $BTMD
    $HOLX
    $MYGN
    $PODD
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

    SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox's responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquis

    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$MYGN
Financials

Live finance-specific insights

See more
  • Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

    SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telep

    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

    SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Select Preliminary Fourth Quarter and Full Year 2024 Financial ResultsThe company expects the following: Fourth quarter of 2024 total revenues to be between $209 million and $211 million, an increase of approximately 6% to 7% compared to fourth quarter of 2023. Full year 2024 total revenues to be between $836 million to $838 million, an increase of approximately 11% compared to full year 202

    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

    Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA increased to $14.1 million from $1.4 million in third quarter of 2023.Third quarter GAAP loss per share improved to $(0.24) from $(0.75) in the third quarter of 2023; adjusted earnings (loss) per share improved to $0.06 from ($0.03) in the third quarter of 2023.Updated 2024 financial

    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$MYGN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more